James Noble has been appointed full-time chief executive officer of Adaptimmune Ltd which is investigating the use of engineered T cells to treat cancer. Mr Noble has been leading both Adaptimmune and its sister company Immunocore. Going forward he will devote his full time to Adaptimmune. Jonathan Knowles, a former executive at Roche and executive chairman of both Adaptimmune and Immunocore, will serve as acting CEO of Immunocore.
Adaptimmune announced the appointment on 26 March 2014.
Copyright 2014 Evernow Publishing Ltd